Published online Apr 28, 2021. doi: 10.13105/wjma.v9.i2.208
Peer-review started: December 30, 2020
First decision: February 28, 2021
Revised: March 3, 2021
Accepted: April 23, 2021
Article in press: April 23, 2021
Published online: April 28, 2021
Processing time: 118 Days and 19.6 Hours
Cardiac syndrome X (CSX) is characterized by persistent angina with normal coronary arteries. Several pathophysiologic mechanisms have been introduced, particularly Helicobacter pylori (H. pylori) infection.
To investigate the association between H. pylori infection and CSX.
All studies related to H. pylori infection and CSX were evaluated by comprehensive searches of global databases such as ISI Web of Knowledge, PubMed, Scopus, EMBASE, and Google scholar. Statistical analyses of selected articles were evaluated based on the summary odds ratio (OR). Finally, heterogeneity and publication bias were estimated using the I2 statistic and Cochrane Q-test as well as Begg’s and Egger’s tests.
A total of 11 studies met our inclusion criteria and 1435 patients (63% female, and 37% male) were reviewed. A significant association was observed between female patients and this syndrome (P = 0.02). Our results showed a positive association between infection with this pathogen and presence of CSX (OR: 5.65; 95% confidence interval [CI]: 4.17-7.64; I2: 82.20). However, no significant association was observed with cagA-positive H. pylori strains and this syndrome (OR: 0.97; 0.56-1.70 with 95%CI). Given the heterogeneity and publication bias, the results need to confirmed by further prospective investigation.
Based on our results, H. pylori infection is associated with an increased risk of CSX. This bacterium appears to play a major role in the pathogenesis of CXS by inducing persistent inflammation.
Core Tip: According to various studies, persistent colonization and chronic inflammation caused by Helicobacter pylori (H. pylori) infection can lead to systemic disorders outside the gastrointestinal tract. Recently, the role of H. pylori in cardiac syndrome X (CSX) has garnered attention. Nevertheless, the mechanism of this syndrome is not fully understood, and it remains controversial. Data from 11 studies were evaluated to assess the association between H. pylori infection and CSX. The results showed that there is a positive association between infection with this bacterium and the development of CSX. It seems that H. pylori increase the risk of CSX through dysregulation of the immune response and alternating epigenetic events. Statistical analyses showed that the presence of CSX was not dependent on cagA status. Several limitations such as small sample size, heterogeneity, and publication bias indicate that confirmation of the present results by further prospective investigation is necessary.
- Citation: Karbalaei M, Sahebkar A, Keikha M. Helicobacter pylori infection and susceptibility to cardiac syndrome X: A systematic review and meta-analysis. World J Meta-Anal 2021; 9(2): 208-219
- URL: https://www.wjgnet.com/2308-3840/full/v9/i2/208.htm
- DOI: https://dx.doi.org/10.13105/wjma.v9.i2.208
Helicobacter pylori (H. pylori) is one of the most important human pathogens in gastric conditions, causing infections in 4-4.5 billion people worldwide[1,2]. This bacterium successfully colonizes in the stomach in childhood and causes chronic infections[3]. After being diagnosed by two Australian physicians, Barry Marshall and Robin Warren in 1994, H. pylori was classified as a class I carcinogen[4] by the International Agency for Research on Cancer. Although 85%-90% of infected individuals remain asymptomatic, 10%-15% of cases progress to severe clinical outcomes such as peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma[5]. Most frequently, this bacterium is transmitted through gastro-oral, fecal-oral, or oral-oral pathways[6]. Today, there is ample evidence that the bacteria are isolated from out-of-stomach sites such as atherosclerotic plaques, synovial fluid and urine, suggesting that H. pylori plays an important role in extra-intestinal disorders by dysregulating immune response or direct attack[7-14]. According to the literature, H. pylori infection is significantly associated with hematological and cardiovascular disorders including iron deficiency anemia, primary immune thrombocytopenia, vitamin B12 deficiency, autoimmune neutropenia, anti-phospholipid syndrome, plasma cell dyscrasias, atherosclerosis, and ischemic stroke[15-22]. Surprisingly, many patients with various disorders such as chest pain, abnormal rest electrocardiogram and positive stress test have normal result of coronary angiogram; this disorder was first named cardiac syndrome X (CSX) by Harvey Kemp in 1973, and then was subsequently termed “angina with normal coronary arteries”[23]. CSX is characterized by a variety of features such as angina-like chest pain, positive exercise testing, positive thallium testing, and normal angiography, and accounts for about 20% of chest pain cases[24-26]. The prevalence of this syndrome is higher in women than in men[27]. Several pathophysiologic mechanisms have been introduced for CSX including inflammation, endothelial dysfunction, genome polymorphism, dyslipidemia, hypertension, smoking, obesity, vasodilator stimuli, and insulin resistance[28-30]. This syndrome has a poor prognosis and may lead to myocardial infarction following repeated hospitalization[31,32]. The exact mechanism of CSX is not fully understood; however, factors such as chronic inflammation, endothelial dysfunction, and microvascular ischemia appear to be the most important risk factors for progression to CSX[33-35]. On the other hand, the role of infectious agents (both viral and bacterial) in susceptibility to cardiovascular diseases (CVDs) has been suggested[36]. According to extant evidence, H. pylori infection leads to CVDs through chronic inflammation and endothelial dysfunction (i.e. morphological and functional alterations in carotid artery or atrial stiffness)[37,38]. According to a case report, eliminating this infection could reduce the incidence of CSX[39]. Although several studies have confirmed the link between infection with H. pylori and this syndrome, there are some studies with controversial results[40,41]. Because no comprehensive study has been performed on the relationship between this infection and CSX, the present meta-analysis was undertaken to evaluate CSX susceptibility in patients with H. pylori.
Initially, a systematic search was performed to evaluate the effects of H. pylori infection on susceptibility to CSX. For this purpose, we focused on global databases such as ISI Web of Knowledge, PubMed, Scopus, EMBASE, and Google Scholar, as well as MeSH-based keywords such as “Helicobacter pylori,” “H. pylori,” and “Cardiac Syndrome X.” Relevant studies were retrieved regardless of publication date and language. The literature search process was conducted separately by two authors (Karbalaei M and Keikha M), and to avoid losing information, the references of each article were evaluated.
The inclusion criteria were: cross-sectional, case-control, original, and cohort studies; studies associated with H. pylori infection and CSX; studies based on standard diagnostic methods for H. pylori infection; and studies on the human population. The exclusion criteria were: review articles, case-reports, and congress abstracts; duplicate studies; repetitive samples; in vitro or animal experiments; and unclear or insufficient data. Finally, 11 eligible studies were selected for analysis in this study[41-51].
At this stage, the Newcastle-Ottawa Scale was used to assess the quality of eligible articles. Required information such as first author, publication year, location of study, number of case-control samples, age, gender distribution, infection frequency, diagnostic methods, and reference number are listed in Table 1.
Ref. | Publication year | Location | Number of cases | Age | Gender (F/M) | Helicobacter pylori infection | Diagnostic method | NOS score | ||||
Case | Control | Case | Control | Case | Control | Case | Control | |||||
Lanza et al[41] | 2004 | Italy | 55 | 60 | 57 ± 8 | 57 ± 1 | 27/28 | 24/36 | 53% | 64% | ELISA | 9 |
Eskandarian et al[42] | 2005 | Iran | 23 | 23 | 42 ± 4 | 41 ± 4 | 17/6 | 16/7 | 91% | 48% | UBT | 7 |
Eskandarian et al[43] | 2006 | Iran | 40 | 40 | 45 ± 5 | 44 ± 4 | 29/11 | 28/12 | 95% | 47.5% | UBT | 7 |
Song et al[44] | 2008 | China | 50 | 50 | NA | NA | NA | NA | 85.2% | 46.7% | UBT | 4 |
Said MohammadZade et al[45] | 2009 | Iran | 54 | 168 | 54.5 | 55.2 | 42/12 | 125/43 | 81.48% | 56.54% | ELISA | 7 |
Assadi et al[46] | 2009 | Iran | 30 | 30 | 53.2 | 52.6 | 18/12 | 18/12 | 50% | 0% | UBT | 6 |
Rasmi et al[47] | 2012 | Iran | 88 | 97 | 53.8 | 45.7 | 56/32 | 61/36 | 98.86% | 57.73% | ELISA | 9 |
Rasmi et al[48] | 2012 | Iran | 100 | 100 | 51.8 | 48.9 | 61/39 | 61/39 | 92% | 56% | ELISA | 9 |
Rasmi et al[49] | 2013 | Iran | 60 | 60 | 51.8 | 48.9 | 38/22 | 39/21 | 95% | 40% | ELISA | 7 |
Rasmi et al[50] | 2016 | Iran | 88 | 97 | 53.8 | 45.7 | 56/32 | 61/36 | 93.18% | 57.73% | ELISA | 6 |
Yu et al[51] | 2018 | China | 61 | 61 | NA | NA | NA | NA | 92.8% | 57.6% | ELISA | 5 |
We pooled the data using statistical analysis software, Comprehensive Meta-Analysis version 2.2 (Biostat, Englewood, NJ, United States). The association between H. pylori infection and incidence of CSX was estimated based on the summary odds ratios (OR) and 95% confidence intervals (Cis). We used the I2 index and the Cochrane Q-test to determine the heterogeneity between studies. Hence, I2 > 50 and Cochrane Q-test P value < 0.05 were considered significant heterogeneity. Furthermore, in both high and low heterogeneity cases, the random-effects model and the fixed-effects model were used, respectively. Publication bias was also examined through funnel plots and Egger’s and Begg’s tests.
In this study, following an initial search in the global databases, we received 206 articles. After evaluating their titles and abstracts and removing duplicate full-text versions, 42 eligible articles were evaluated according to our inclusion criteria, and finally 11 articles were selected (Figure 1).
All selected studies were conducted during 2004-2018, and the geographical distribution of the articles was limited to some countries such as Iran, China, and Italy. In eligible studies, the enzyme-linked immunoassay and urea breath test were used to diagnose H. pylori. In this meta-analysis, data from 1,435 participants including 649 CSX patients and 786 controls were evaluated. All cases of CSX were diagnosed by typical history of angina with normal or near normal coronary angiography plus a positive none-invasive test or abnormal ECG diagram. Of all patients, 36.61% were male and the rest were female. There was a significant relationship between female sex and getting CSX (P = 0.02); the mean ages of patients and the controls were 51.48 and 48.81, respectively. Despite the positive correlation in most studies, in three studies, this relationship was inconsistent, even the relationship between the cagA gene and CSX[47-49]. In general, all eligible studies evaluated factors including hypertension, diabetes, hyperlipidemia, smoking, systolic/diastolic blood pressure values, serum homocysteine levels, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride.
Statistical analyses showed that the frequency of infection with H. pylori in CSX patients was 77.3% (95%CI: 71.7-82, P = 0.01, I2 = 89.47, Q = 66.51, P = 0.01; Begg’s P = 0.86; Egger’s P = 0.01), while that of infection in healthy individuals was 54.2% (95%CI: 50-58.3, P = 0.05; I2 = 60.7, Q = 17.82, P = 0.01; Begg’s P = 0.13; Egger’s P = 0.03). Based on the summary OR, we found a strong positive association between this infection and CSX (OR: 5.65, 95%CI: 4.17-7.64, P = 0.01, I2 = 82.20, Q = 56.19, P = 0.01; Begg’s P = 0.40; Egger’s P = 0.21), suggesting that patients infected with H. pylori might be more susceptible to progression to CSX (Figure 2).
CagA is regarded as one of the main bacterial factors causing alterations in normal signaling pathways and dysregulation of actin-rearrangement, as well as induction of chronic and severe immune responses[52,53]. Based on statistical analyses, no significant relationship was observed between cagA-positive strains and susceptibility to CSX (OR: 0.97; 95%CI: 0.56-1.70; P = 0.93, I2 = 0.00, Q = 0.006, P = 0.96). According to the literature, hypertension and hyperlipidemia are the most important CSX-related factors caused by chronic inflammation[31,54,55]. H. pylori infection via dysregulating the immune system (MALT lymphogenesis) may lead to disruption of normal homeostasis and basal metabolism, and eventually cardiovascular risk[56-60]. Our results also indicate a positive significant relationship between infection caused by this bacterium and the presence of hyperlipidemia/ hypertension in CSX patients (OR: 3.33; 95%CI: 1.92-5.76; and OR: 2.30; 95%CI: 1.37-3.87, respectively). About 14.1% of CSX patients were smokers; however, there was no significant association between smoking and the risk of CSX (OR: 0.95, 95%CI: 0.62-1.45, P = 0.83).
In the present meta-analysis, we evaluated publication bias using several tests such as Begg’s, Egger’s, and funnel plot evaluation (Figure 3). According to the results, there was significant publication bias that seems to be due to the low number of available articles.
CSX is one of the heterogeneous syndromes in which cardiac (malfunction of Na-H+ pump, smooth muscle cell migration, endothelial dysfunction, etc.) and non-cardiac (sympathetic reactions, inflammation) mechanisms are involved[61]. Although CSX is a multifactorial disease, the most important pathological factors associated with this syndrome are endothelial dysfunction, coronary artery disease, and myocardial ischemia[62,63]. Recently, the role of inflammation in pathogenesis of CSX, has been defined[64,65]. Pro-inflammatory cytokines, especially interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α), cause several pathological changes, such as endothelial dysfunction, motility vessels, and microvascular stenosis, which in turn predispose to CSX[66]. In general, infectious agents are considered risk factors for CVDs due to long-term stimulation of the immune response[67]. Today, the role of H. pylori infection in CVDs immunopathogenesis has received increasing attention[68]. Immune responses (e.g., cytokines and reactive oxygen species) against this pathogen lead to extracellular disorders[69,70]. Innocenti et al[71] showed that this bacterium can activate endothelial cells. In another study, Oshima et al[72] found that complications such as systemic inflammation and endothelial dysfunction were more common in patients infected with H. pylori than in healthy individuals. In this study, we performed a comprehensive analysis of this association, and finally the results showed that there is a meaningful positive relationship between infection with this bacterium and CSX (OR: 5.65; 4.17-7.64 with 95%CIs). In their study, Rasmi et al[47] also showed a significant correlation between these two events in the Iranian population. Moreover, according to a study by Nocente et al[39], eliminating infection can significantly contribute to CSX regression. Our results also showed that the rate of H. pylori infection is higher in CSX patients than in nested-healthy controls (77.3% vs 54.2%). The bacterium contains various virulence factors that act as bacterial super-antigens, and stimulate lamina propria macrophages and local T cells[73]. During the infection, inflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α increase the infiltration of leucocytes, and aggregation of platelets and PMNs into the site of infection. Bacteria cause some events such as platelet activation and endothelial dysfunction by increasing von Willebrand factor[74,75]. Chemokine receptors such as E-selectin, P-selectin, and intercellular adhesion molecule 1 damage endothelial vessels by increasing the influx of leukocytes[76]. Cannon et al[77] showed that the number of chemokine receptors in CSX patients was higher than that in the control group. Other parameters such as serum fibrinogen level, and white blood cell or platelet count in patients with long-term infection are significantly higher than those in the control group[78,79]. Lanza et al[41] found that IL-1/C-reactive protein levels were higher in CSX patients than in the healthy group, so they identified these as CSX biomarkers. Chronic infection may cause several disorders, such as motility vessel, contraction of small vessels, and eventually endothelial dysfunction, by inducing inflammation and increasing immune responses[80-82]. The phenomenon of cross-reaction between H. pylori antigens and autoantigens increases endothelial damage[83]. Although CagA antigen is a known virulence factor that is associated with complications such as peptic ulcer disease and gastric cancer, no significant relationship was found between the cagA status and CSX disease (OR: 0.97; 0.56-1.70 with 95%CIs). Risk factors such as hypertension, hyperlipidemia, diabetes mellitus, smoking, and alcoholism are among major risk factors for CSX[84,85]. In general, inflammatory responses to chronic infections dysregulate the basal metabolism; for example, IL-6 affects the liver and increases gluconeogenesis and synthesis of fatty acids[86-90]. Another inflammatory cytokine, TNF-α, reduces the clearance of blood fat particles by blocking liver lipoprotein lipase, thus, it is associated with hyperlipidemia[91-93]. Nowadays, there is ample evidence of a positive correlation between chronic H. pylori infection and hypertension. In the study conducted by Migneco et al[94], it was shown that complete eradication of infection with these bacteria significantly reduced hypertension in infected patients[93]. Based on previous studies, this bacterium affects the immune system, leading to defects in lipid metabolism and eventually hyperlipidemia[95-98]. In general, prolonged H. pylori infection leads to extra-gastrointestinal complications such as motility vessel, microvascular constriction, endothelial dysfunction, hypertension, and hyperlipidemia, and at the end CSX (Figure 4).
Our meta-analysis had several limitations such as: small number of participants, limited geographical distribution, high heterogeneity, significant publication bias, and lack of adjustment for covariates such as age and CV risk factors, nature of studies (case-control and no cohort), and lack of access to raw data such as socio-economic status, alcohol consumption, and environmental hygiene. However, due to heterogeneity, we need further research to confirm the present findings.
The present study was the first comprehensive study to evaluate the relationship between H. pylori infection and CSX. Overall, our results suggested an association between H. pylori infection and the risk of CSX; however, we need further research with larger sample sizes to confirm the present findings. In this study, using a systematic review, we showed that H. pylori infection increases the risk of developing the CSX disease through inflammation, endothelial damage, and the effect on related risk factors.
Cardiac syndrome X (CSX) is multilateral condition that not well characterized.
For the first time, we investigated the probable association between Helicobacter pylori (H. pylori) infection and risk of develop to cardiac syndrome.
In the present study, the association between H. pylori infection and CSX was investigated.
We searched several databases to collecting all available documents relevant to impact of H. pylori infection and susceptibility to CSX. odds ratio (OR) is used for estimation of probable link between H. pylori infection and CSX.
There is a positive association between H. pylori infection and risk of develop to CSX (OR: 5.65, 95%CI: 4.17-7.64, I2: 82.20).
In this study, we found that H. pylori infection increases the risk of CSX. We showed that there is no significant relationship between cagA status and progression to CSX. The frequency of vascular endothelial destructive risk factors such as hyperlipidemia and hypertension in patients infected with H. pylori was significantly higher than the control group.
Infectious agents such as H. pylori infection can provide a condition to susceptibility of CSX.
Manuscript source: Invited manuscript
Corresponding Author's Membership in Professional Societies: Iran Society for Infectious Disease.
Specialty type: Infectious diseases
Country/Territory of origin: Iran
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): D
Grade E (Poor): 0
P-Reviewer: Koller T, Modun D S-Editor: Wang JL L-Editor: Filipodia P-Editor: Li X
1. | Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449-490. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1446] [Cited by in F6Publishing: 1455] [Article Influence: 80.8] [Reference Citation Analysis (1)] |
2. | Roesler BM, Rabelo-Gonçalves EM, Zeitune JM. Virulence Factors of Helicobacter pylori: A Review. Clin Med Insights Gastroenterol. 2014;7:9-17. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 82] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis (0)] |
3. | Magalhães Queiroz DM, Luzza F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2006;11 Suppl 1:1-5. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis (0)] |
4. | liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241. [PubMed] [Cited in This Article: ] |
5. | Robinson K, Atherton JC. The Spectrum of Helicobacter-Mediated Diseases. Annu Rev Pathol. 2021;16:123-144. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 33] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis (0)] |
6. | Kivi M, Tindberg Y. Helicobacter pylori occurrence and transmission: a family affair? Scand J Infect Dis. 2006;38:407-417. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
7. | Allaker RP, Young KA, Hardie JM, Domizio P, Meadows NJ. Prevalence of helicobacter pylori at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission. J Med Microbiol. 2002;51:312-317. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
8. | Graff LB, Andersen LP, Gernow A, Bondesen S, Bremmelgaard A, Bonnevie O, Danneskiold-Samsoe B, Bartels EM. Effect of eradication of Helicobacter pylori in rheumatoid arthritis patients. J Pre Clin Clin Res. 2007;1:74-79. [Cited in This Article: ] |
9. | Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut. 2001;48:287-289. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 120] [Cited by in F6Publishing: 123] [Article Influence: 5.3] [Reference Citation Analysis (0)] |
10. | Hasni S, Ippolito A, Illei GG. Helicobacter pylori and autoimmune diseases. Oral Dis. 2011;17:621-627. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
11. | Costa AC, Figueiredo C, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2009;14 Suppl 1:15-20. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis (0)] |
12. | Petersen AM, Krogfelt KA. Helicobacter pylori: an invading microorganism? FEMS Immunol Med Microbiol. 2003;36:117-126. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
13. | Huang Y, Wang QL, Cheng DD, Xu WT, Lu NH. Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter pylori. Front Cell Infect Microbiol. 2016;6:159. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 85] [Article Influence: 10.6] [Reference Citation Analysis (0)] |
14. | Silva DG, Stevens RH, Macedo JM, Albano RM, Falabella ME, Veerman EC, Tinoco EM. Detection of cytotoxin genotypes of Helicobacter pylori in stomach, saliva and dental plaque. Arch Oral Biol. 2009;54:684-688. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
15. | Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter. 2008;13:323-340. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 8.1] [Reference Citation Analysis (0)] |
16. | Veneri D, Krampera M, Franchini M. Helicobacter pylori infection and idiopathic thrombocytopenic purpura: description of 21 newly diagnosed cases. Haematologica. 2004;89:ECR08. [PubMed] [Cited in This Article: ] |
17. | Lahner E, Persechino S, Annibale B. Micronutrients (Other than iron) and Helicobacter pylori infection: a systematic review. Helicobacter. 2012;17:1-15. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
18. | Cicconi V, Carloni E, Franceschi F, Nocente R, Silveri NG, Manna R, Servidei S, Bentivoglio AR, Gasbarrini A, Gasbarrini G. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am J Med. 2001;111:163-164. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
19. | Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018;24:3204-3221. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 162] [Cited by in F6Publishing: 151] [Article Influence: 25.2] [Reference Citation Analysis (5)] |
20. | Wang B, Yu M, Zhang R, Chen S, Xi Y, Duan G. A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease. Helicobacter. 2020;25:e12761. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis (0)] |
21. | Wang ZW, Li Y, Huang LY, Guan QK, Xu DW, Zhou WK, Zhang XZ. Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis. J Neurol. 2012;259:2527-2537. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis (0)] |
22. | El-Said H, Attallah AHB, Ali-Eldin ZA. Does Helicobacter pylori infection play a role in iron deficiency anemia in hemodialysis patients? Clin Nephrol. 2017;88:177-180. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
23. | Kret M. [Cardiac syndrome X--epidemiology, diagnostics, ethiopatoghenesis, prognosis, treatment and latest guidelines]. Przegl Lek. 2016;73:40-45. [PubMed] [Cited in This Article: ] |
24. | Agrawal S, Mehta PK, Bairey Merz CN. Cardiac Syndrome X: update 2014. Cardiol Clin. 2014;32:463-478. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
25. | de la Peña M, Barceló A, Barbe F, Piérola J, Pons J, Rimbau E, Ayllón O, Agustí AG. Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration. 2008;76:28-32. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
26. | Cotrim C, Almeida AG, Carrageta M. Cardiac syndrome X, intraventricular gradients and, beta-blockers. Rev Port Cardiol. 2010;29:193-203. [PubMed] [Cited in This Article: ] |
27. | Kaski JC. Cardiac syndrome X in women: the role of oestrogen deficiency. Heart. 2006;92 Suppl 3:iii5-iii9. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
28. | Desideri G, Gaspardone A, Gentile M, Santucci A, Gioffrè PA, Ferri C. Endothelial activation in patients with cardiac syndrome X. Circulation. 2000;102:2359-2364. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
29. | Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation. 2004;109:568-572. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
30. | Kaski JC. Overview of gender aspects of cardiac syndrome X. Cardiovasc Res. 2002;53:620-626. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
31. | Lanza GA. Cardiac syndrome X: a critical overview and future perspectives. Heart. 2007;93:159-166. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 102] [Cited by in F6Publishing: 90] [Article Influence: 5.0] [Reference Citation Analysis (0)] |
32. | Kolasińska-Kloch W, Furgała A, Królczyk G, Kloch M, Szumańska M, Laskiewicz J, Thor PJ. Cardiac syndrome X--autonomic system disorders. Folia Med Cracov. 2004;45:19-29. [PubMed] [Cited in This Article: ] |
33. | Rasmi Y, Rouhrazi H, Khayati-Shal E, Shirpoor A, Saboory E. Association of endothelial dysfunction and cytotoxin-associated gene A-positive Helicobacter pylori in patients with cardiac syndrome X. Biomed J. 2016;39:339-345. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
34. | Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging. 2013;6:660-667. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 107] [Cited by in F6Publishing: 126] [Article Influence: 11.5] [Reference Citation Analysis (0)] |
35. | Jones E, Eteiba W, Merz NB. Cardiac syndrome X and microvascular coronary dysfunction. Trends Cardiovasc Med. 2012;22:161-168. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
36. | Strandberg TE, Pitkala KH, Linnavuori KH, Tilvis RS. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke. 2003;34:2126-2131. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
37. | Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Hafner G, Pfeifer U, Meyer J. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke. 2000;31:2127-2133. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
38. | Saijo Y, Utsugi M, Yoshioka E, Horikawa N, Sato T, Gong Y, Kishi R. Relationship of Helicobacter pylori infection to arterial stiffness in Japanese subjects. Hypertens Res. 2005;28:283-292. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
39. | Nocente R, Gentiloni N, Cremonini F, Giorgi A, Serricchio M, Santoliquido A, Gasbarrini G, Gasbarrini A. Resolution of syndrome X after eradication of virulent CagA-positive Helicobacter pylori. South Med J. 2000;93:1022-1023. [PubMed] [Cited in This Article: ] |
40. | Rasmi Y, Raeisi S. Possible role of Helicobacter pylori infection via microvascular dysfunction in cardiac syndrome X. Cardiol J. 2009;16:585-587. [PubMed] [Cited in This Article: ] |
41. | Lanza GA, Sestito A, Cammarota G, Grillo RL, Vecile E, Cianci R, Speziale D, Dobrina A, Maseri A, Crea F. Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol. 2004;94:40-44. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
42. | Eskandarian R, Malek M, Mousavi S, Babai M. Association of helicobacter pylori infection with cardiac syndrome X. Koomesh J. 2005;6:131. [Cited in This Article: ] |
43. | Eskandarian R, Malek M, Mousavi SH, Babaei M. Association of Helicobacter pylori infection with cardiac syndrome X. Singapore Med J. 2006;47:704-706. [PubMed] [Cited in This Article: ] |
44. | Song YH, Dai YG, Cai LA. Association of helicobacter pylori infection with cardiac syndrome X. Zhongguo Xinxueguanbingyanjiu Zazhi. 2007;5:456-458. [DOI] [Cited in This Article: ] |
45. | Said MohammadZade M, Eishi A, Behrozian R, Rahimi E. Relationship between Helicobacter pylori infection and cardiac syndrome X. J Shahrekord University Med Sci. 2009;11:58-63. [Cited in This Article: ] |
46. | Assadi M, Saghari M, Ebrahimi A, Reza Pourbehi M, Eftekhari M, Nabipour I, Abbaszadeh M, Nazarahari M, Nasiri M, Assadi S. The relation between Helicobacter pylori infection and cardiac syndrome X: a preliminary study. Int J Cardiol. 2009;134:e124-e125. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
47. | Rasmi Y, Seyyed-Mohammadzad MH. Frequency of Helicobacter pylori and cytotoxine associated gene A antibodies in patients with cardiac syndrome X. J Cardiovasc Dis Res. 2012;3:19-21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
48. | Rasmi Y, Seyed-Mohammadzad M, Raeisi S. Relationship between high sensitivity C-reactive protein and CagA positive Helicobacter Pylori in cardiac syndrome X. J Sci Res. 2013;5:527-533. [DOI] [Cited in This Article: ] |
49. | Rasmi Y, Mehraban K, Sadreddini M, Zeynalzadeh J, Majidinia M, Seyyed-Mohammadzad M, Babazadeh H. Lack of significant association between Helicobacter pylori infection and homocysteine levels in patients with cardiac syndrome X. Cardiol J. 2012;19:466-469. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
50. | Rasmi Y, Zeynalzadeh J, Shirpoor A, Seyedmohammadzad M, Hajhosseini R. Lipid Profile in Cardiac Syndrome X: Association with Helicobacter pylori. J Clin Diagn Res. 2016;10:BC07-BC09. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
51. | Yu ZH, Lu KJ, Chen ZF. HP Correlation analysis of HP infection, blood homocysteine level and CSX. Zhejiang Linchuang Yixue. 2018;20:1012-1013. [Cited in This Article: ] |
52. | Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factor Cytotoxin-Associated Gene A (CagA)-Mediated Gastric Pathogenicity. Int J Mol Sci. 2020;21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
53. | Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, Norelli F, Contorni M, Peppoloni S, Berti D, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt BF, Del Giudice G. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology. 2008;135:787-795. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 7.5] [Reference Citation Analysis (0)] |
54. | Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, Altas Y, Aydin S. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther. 2013;31:174-178. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 56] [Cited by in F6Publishing: 63] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
55. | Kaski JC, Aldama G, Cosín-Sales J. Cardiac syndrome X. Diagnosis, pathogenesis and management. Am J Cardiovasc Drugs. 2004;4:179-194. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
56. | Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of Helicobacter pylori: a concise review. World J Gastroenterol. 2014;20:11950-11961. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis (0)] |
57. | Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? J Dig Dis. 2012;13:342-349. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis (0)] |
58. | Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48:751-762. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 470] [Cited by in F6Publishing: 510] [Article Influence: 30.0] [Reference Citation Analysis (0)] |
59. | Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol. 2008;103:3005-3010. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 6.7] [Reference Citation Analysis (0)] |
60. | Shin DW, Kwon HT, Kang JM, Park JH, Choi HC, Park MS, Park SM, Son KY, Cho B. Association between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological status. J Clin Gastroenterol. 2012;46:840-845. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis (0)] |
61. | Crea F. Prevalence, pathogenesis, diagnosis and treatment of cardiac syndrome X. E-J Cardiol Pra. 2003;1:1. [Cited in This Article: ] |
62. | Arroyo-Espliguero R, Kaski JC. Microvascular dysfunction in cardiac syndrome X: the role of inflammation. CMAJ. 2006;174:1833. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
63. | Marwick TH. Ischaemia and outcome with normal coronary arteries. Eur Heart J. 2005;26:2077-2078. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
64. | Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15:505-522. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1710] [Cited by in F6Publishing: 1764] [Article Influence: 294.0] [Reference Citation Analysis (0)] |
65. | Vermeltfoort IA, Raijmakers PG, Riphagen II, Odekerken DA, Kuijper AF, Zwijnenburg A, Teule GJ. Definitions and incidence of cardiac syndrome X: review and analysis of clinical data. Clin Res Cardiol. 2010;99:475-481. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
66. | Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, Li H, Lamas S, Münzel T. Targeting vascular (endothelial) dysfunction. Br J Pharmacol. 2017;174:1591-1619. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 339] [Cited by in F6Publishing: 304] [Article Influence: 43.4] [Reference Citation Analysis (0)] |
67. | Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35:1373-1381. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 142] [Cited by in F6Publishing: 171] [Article Influence: 17.1] [Reference Citation Analysis (0)] |
68. | Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol. 2014;11:234-242. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 10.4] [Reference Citation Analysis (0)] |
69. | Chmiela M, Gajewski A, Rudnicka K. Helicobacter pylori vs coronary heart disease - searching for connections. World J Cardiol. 2015;7:187-203. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
70. | Tsay FW, Hsu PI. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci. 2018;25:65. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 11.7] [Reference Citation Analysis (0)] |
71. | Innocenti M, Thoreson AC, Ferrero RL, Strömberg E, Bölin I, Eriksson L, Svennerholm AM, Quiding-Järbrink M. Helicobacter pylori-induced activation of human endothelial cells. Infect Immun. 2002;70:4581-4590. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
72. | Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, Yoshizumi M, Kambe M. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol. 2005;45:1219-1222. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 98] [Cited by in F6Publishing: 112] [Article Influence: 5.9] [Reference Citation Analysis (0)] |
73. | Robinson K, Argent RH, Atherton JC. The inflammatory and immune response to Helicobacter pylori infection. Best Pract Res Clin Gastroenterol. 2007;21:237-259. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
74. | Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam. 2011;2011:908468. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 91] [Cited by in F6Publishing: 132] [Article Influence: 10.2] [Reference Citation Analysis (0)] |
75. | Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, Fitzgerald DJ, Cox DM. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology. 2003;124:1846-1854. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 126] [Cited by in F6Publishing: 130] [Article Influence: 6.2] [Reference Citation Analysis (0)] |
76. | Barac A, Campia U, Panza JA. Methods for evaluating endothelial function in humans. Hypertension. 2007;49:748-760. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 94] [Cited by in F6Publishing: 101] [Article Influence: 5.9] [Reference Citation Analysis (0)] |
77. | Cannon RO 3rd. Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol. 2009;54:877-885. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 97] [Cited by in F6Publishing: 91] [Article Influence: 6.1] [Reference Citation Analysis (0)] |
78. | Liuba P, Pesonen E, Paakkari I, Batra S, Andersen L, Forslid A, Ylä-Herttuala S, Persson K, Wadström T, Wang X, Laurini R. Co-infection with Chlamydia pneumoniae and Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1 expression in apoE-knockout mice. J Vasc Res. 2003;40:115-122. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
79. | Tsai WC, Li YH, Sheu BS, Tsai LM, Chao TH, Lin LJ, Chen JH. Association of elevation of anti-Helicobacter pylori antibody with myocardial ischemic events in coronary artery disease. Am J Cardiol. 2001;87:1005-7; A5. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
80. | Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc. 2004;96:1470-1476. [PubMed] [Cited in This Article: ] |
81. | Su YC, Wang WM, Wang SY, Lu SN, Chen LT, Wu DC, Chen CY, Jan CM, Horowitz M. The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1900-1905. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
82. | Stöllberger C, Finsterer J. Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis. Clin Diagn Lab Immunol. 2002;9:207-215. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
83. | Ammann P, Marschall S, Kraus M, Schmid L, Angehrn W, Krapf R, Rickli H. Characteristics and prognosis of myocardial infarction in patients with normal coronary arteries. Chest. 2000;117:333-338. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
84. | Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62-67. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1710] [Cited by in F6Publishing: 1586] [Article Influence: 51.2] [Reference Citation Analysis (0)] |
85. | Balta S, Cakar M, Demirkol S, Unlu M, Demirbas S. Helicobacter pylori infection and homocysteine levels in patients with cardiac syndrome X. Cardiol J. 2013;20:329. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
86. | Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B, Zhang M, Zhang X, Zhang C, Li M, Sun L, Xue Z, Wang J, Feng J, Yan F, Zhao N, Liu J, Long W, Zhao L. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014;87:357-367. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 239] [Cited by in F6Publishing: 273] [Article Influence: 24.8] [Reference Citation Analysis (0)] |
87. | Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010;2010. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 583] [Cited by in F6Publishing: 722] [Article Influence: 51.6] [Reference Citation Analysis (0)] |
88. | Guerrero-Romero F, Rodríguez-Morán M. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab Res Rev. 2006;22:471-476. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 4.7] [Reference Citation Analysis (0)] |
89. | Blumberg D, Hochwald S, Brennan MF, Burt M. Interleukin-6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. Metabolism. 1995;44:145-146. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
90. | Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372-1379. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 395] [Cited by in F6Publishing: 428] [Article Influence: 26.8] [Reference Citation Analysis (0)] |
91. | Chen X, Xun K, Chen L, Wang Y. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct. 2009;27:407-416. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 138] [Cited by in F6Publishing: 156] [Article Influence: 10.4] [Reference Citation Analysis (0)] |
92. | Kiely A, McClenaghan NH, Flatt PR, Newsholme P. Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic beta-cell line. J Endocrinol. 2007;195:113-123. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
93. | Kim YI, Kim YA, Lee JW, Kim HJ, Kim SH, Kim SG, Kim JI, Kim JJ, Choi IJ. Effect of Helicobacter pylori Treatment on Long-term Mortality in Patients with Hypertension. Gut Liver. 2020;14:47-56. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
94. | Migneco A, Ojetti V, Specchia L, Franceschi F, Candelli M, Mettimano M, Montebelli R, Savi L, Gasbarrini G. Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter. 2003;8:585-589. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
95. | Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter. 2009;14:144-150. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 70] [Cited by in F6Publishing: 86] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
96. | Kucukazman M, Yavuz B, Sacikara M, Asilturk Z, Ata N, Ertugrul DT, Yalcin AA, Yenigun EC, Kizilca G, Okten H, Akin KO, Nazligul Y. The relationship between updated Sydney System score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig Dis Sci. 2009;54:604-607. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis (0)] |
97. | Nam SY, Ryu KH, Park BJ, Park S. Effects of Helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter. 2015;20:125-132. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis (0)] |
98. | Haeri M, Parham M, Habibi N, Vafaeimanesh J. Effect of Helicobacter pylori Infection on Serum Lipid Profile. J Lipids. 2018;2018:6734809. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis (0)] |